VG
Publicaties op Oncologisch.com
Brief Report: Post Hoc Validation of Platinum Ineligibility in NSCLC From the Fase III IPSOS Study.
Efficacy and safety of eerstelijns maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-...
Atezolizumab plus cabozantinib versus docetaxel bij gemetastaseerd NSCLC: CONTACT-01 fase III
Atezolizumab plus neoadjuvante anti-HER2 en chemotherapie bij HER2-positief mammacarcinoom: IMpassion050 fase III
Atezolizumab plus carboplatine-nab-paclitaxel bij plaveiselcel-NSCLC: IMpower131 fase III